5 Under the Radar Pharma Stocks in India

5 under-the-radar pharma stocks: MCap Rs 14,787-46,260 Cr. 3 trade below sector PE 37.21. Best ROE: 23.33% (Ajanta Pharma). Lowest D/E: 0.00 (Caplin Point).

Under the radar pharma stocks in India rarely get the analyst note that follows every new USFDA plant reinspection result at Sun Pharma or a US generic filing at Cipla. Yet several mid-tier Indian pharmaceutical companies are building strong export pipelines, maintaining USFDA and EU GMP compliance, and delivering consistent ROE without the crowded institutional ownership of the large-cap pharma names.

India’s pharmaceutical industry is the world’s third-largest by volume, and the export opportunity in branded generics, API, and emerging market supply is growing steadily. The five overlooked pharma stocks below each serve differentiated parts of this ecosystem, with data .

Click Here – Get Free Investment Predictions

What Are Pharma Stocks in India?

Under the radar pharma stocks are smallcap and midcap Indian pharmaceutical companies with proven export capabilities, API leadership, or strong branded generics positions in regulated markets that receive limited mainstream analyst attention compared to the sector’s large-cap leaders. These pharma stocks are the focus of this article.

5 Pharma Stocks Flying Under the Radar in India

The table below lists 5 pharma stocks . Data from NSE filings. Sector average PE: 37.21x. Verify on nseindia.com before investing in any of these pharma stocks.

1. Caplin Point Laboratories (CAPLIPOINT): One of the Top pharma stocks to Watch

Caplin Point Laboratories is a Chennai-based pharmaceutical company supplying injectable and oral solid generics primarily to Latin America (French-speaking Africa and Francophone markets) through a vertically integrated model. It runs its own marketing subsidiaries in these markets, capturing distribution margins that pure API or product suppliers miss. CMP is approximately Rs 2,530 with a market cap of Rs 19,232 crore.

Caplin Point has the best combined quality profile among these under the radar pharma stocks: zero debt (D/E 0.00), PE 28.36 well below the sector average of 37.21, ROE 17.88%, and EPS (TTM) Rs 89.20. Its Latin America-dominated export model means it is essentially uncorrelated to the US USFDA pricing pressure that weighs on most Indian pharma companies. As tracked on Nifty Pharma, the Pharmaceuticals sector PE stands at 37.21x.

The concentration risk is geographic and model-specific: Caplin is highly dependent on Latin American and Francophone Africa markets. Any political instability, currency devaluation, or regulatory change in those markets directly hits revenue. Diversifying beyond these markets into more competitive geographies is a long-term growth challenge.

2. Neuland Laboratories (NEULAND): One of the Top pharma stocks to Watch

Neuland Laboratories is a Hyderabad-based API manufacturer supplying active pharmaceutical ingredients to global innovator and generic companies across the US, EU, and Japan. It has a Clean Rooms manufacturing facility and supplies complex API molecules. CMP is approximately Rs 23,318 with a market cap of Rs 29,919 crore.

Neuland has the strongest ROE on this list at 19.42%, combined with a reasonable D/E of 0.16. PE is 60.11, above the sector average of 37.21, reflecting its growing pipeline of complex API projects and regulatory clearances in major regulated markets. EPS (TTM) is Rs 387.98. Complex API manufacturing commands higher margins than standard generics and is more defensible against price competition. The Pharmaceuticals sector PE stands at 37.21x.

At PE 60.11, Neuland is priced for continued growth. Any FDA inspection issue at its Hyderabad facility or loss of a major API customer would significantly impact revenue given the company’s moderate scale. API supply agreements with large pharma companies also typically favour the buyer on pricing over contract terms.

3. Marksans Pharma (MARKSANS): One of the Top pharma stocks to Watch

Marksans Pharma is a Mumbai-based pharmaceutical company specialising in branded over-the-counter and prescription generics for the UK, Australia, the US, and other regulated markets. CMP is approximately Rs 326 with a market cap of Rs 14,787 crore.

Marksans is one of the few Indian pharma companies with a meaningful UK and Australia branded generic presence, giving it geographic diversification away from the intensely competitive US generics market. PE is 28.37, below the sector average of 37.21. ROE is 13.82% and D/E is 0.11. EPS (TTM) is Rs 11.50. The UK and Australia markets have better generic pricing dynamics than the US, supporting margin stability. The Pharmaceuticals sector PE stands at 37.21x.

Marksans is small enough that a single product discontinuation or regulatory rejection can meaningfully affect earnings. The UK branded generic business requires sustained marketing investment to defend market positions against new generic entrants in individual drug markets.

4. Sudeep Pharma (SUDEEPPHARMA): One of the Top pharma stocks to Watch

Sudeep Pharma is a specialty pharmaceutical company with manufacturing capabilities across multiple dosage forms including injectables, APIs, and oral solid dosage forms for domestic and international markets. CMP is approximately Rs 1,101 with a market cap of Rs 12,438 crore.

Sudeep Pharma has an ROE of 19.57%, the second highest on this list of under the radar pharma stocks, and a manageable D/E of 0.17. PE is 67.72, above the sector average, reflecting growth expectations. EPS (TTM) is Rs 16.26. The injectable dosage form segment requires significant manufacturing investment and regulatory clearances that create meaningful barriers to entry for competitors. The Pharmaceuticals sector PE stands at 37.21x.

The PE of 67.72 is a premium that requires sustained earnings delivery to justify. Pharma manufacturing is regulated and any FDA inspection outcome or quality system failure can materially disrupt production and revenue. Ongoing regulatory compliance costs are significant.

5. Ajanta Pharma (AJANTPHARM): One of the Top pharma stocks to Watch

Ajanta Pharma is a Mumbai-based company specialising in branded generics for African, Asian, and Middle Eastern emerging markets as well as US generics. Its dermatology and ophthalmology branded segments in Africa have built strong brand equity. CMP is approximately Rs 3,703 with a market cap of Rs 46,260 crore.

Ajanta Pharma has the strongest ROE on this list at 23.33% and near-zero debt (D/E 0.06). PE is 40.76, marginally above the sector average of 37.21, a small premium for superior quality. EPS (TTM) is Rs 90.82 and dividend yield is 0.76%. Its Africa and Asia branded generic model generates higher margins than pure-play US generics competitors and is less vulnerable to US pricing pressure. The Pharmaceuticals sector PE stands at 37.21x.

Africa and Asian branded generic businesses require sustained salesforce investment. Any deterioration in the political or regulatory environment in key African markets, or a currency devaluation in those markets, can hit reported revenue and margins. The US generics pipeline also faces standard generic pricing erosion.

Use the Univest Screener to filter pharma stocks by PE, ROE, D/E, and dividend yield — find more pharma stocks on your own.

Download the Univest iOS App or Univest Android App to get live NSE data and track pharma stocks across every sector..

Why Do These Pharma Stocks Stay Under the Radar?

Mid-tier pharmaceutical companies in India stay under the radar because institutional pharma analysts are stretched covering the large-cap names (Sun, Cipla, Lupin, Dr Reddy’s). Companies like Caplin Point (Latin America specialist) and Marksans (UK/Australia specialist) operate in geographies that most India-focused pharma analysts don’t know as well as the US generics market.

The sector also went through a prolonged US generics price erosion cycle in 2017-2022 that damaged sentiment toward all Indian pharma companies, including those with no US exposure. That broad sector de-rating gave way to recovery from 2023, but the mid-tier names lagged the large-cap recovery in institutional flows.

Key Factors to Evaluate These Pharma Stocks

Before investing in any of these pharma stocks, review these five parameters:

• Export geography diversification: Companies with US-independent export exposure (Caplin Point in Latin America, Marksans in UK/Australia, Ajanta in Africa/Asia) are more insulated from US generic pricing cycles. This is the key differentiator among these under the radar pharma stocks.
• Zero to low debt: Caplin Point at 0.00 and Ajanta Pharma at 0.06 D/E are the balance sheet leaders. Pharma R&D and regulatory compliance are ongoing cash consumers; companies with clean balance sheets can sustain this investment without stress.
• ROE above 15%: Ajanta (23.33%), Neuland (19.42%), and Sudeep Pharma (19.57%) all clear this bar strongly. Caplin (17.88%) and Marksans (13.82%) are slightly below but still solid.
• PE vs sector PE: The sector PE is 37.21. Caplin Point (28.36) and Marksans (28.37) trade below that. Ajanta (40.76) is marginally above. Neuland (60.11) and Sudeep (67.72) carry growth premiums.
• Regulatory compliance track record: Zero USFDA warning letters or import alerts is a critical qualifier for any pharma investment. Always verify current compliance status on the USFDA database before investing in any of these hidden pharma stocks.

Risks in Under the Radar Pharma Stocks

Every investment in pharma stocks carries risk. The four primary risks are:

• USFDA/EU GMP inspection risk: Any import alert or warning letter from a major regulatory body directly impacts revenue from that geography. For pharma companies, regulatory compliance is an ongoing operating risk rather than a one-time event.
• US generic pricing erosion: For companies with US exposure (Neuland, Marksans), the structural decline in US generic prices is a persistent earnings headwind. Companies need to continuously file new products to offset pricing erosion on existing products.
• Geographic concentration: Caplin’s Latin America exposure and Ajanta’s Africa exposure both carry country-specific currency and political risk. Any crisis in a key market geography can hit annual revenue meaningfully.
• R&D pipeline uncertainty: Pharmaceutical revenue depends on new product filings and approvals. Delays in new product approvals can create earnings gaps even when the existing product portfolio is performing well.

How to Invest in Overlooked Pharma Stocks in India

Always check the USFDA and EMA regulatory databases for current inspection status before investing in any Indian pharma company, including these under the radar pharma stocks. A clean regulatory track record is a non-negotiable starting point.

Track new drug approvals from USFDA (ANDA approvals) and UK MHRA for each company. Rising approval counts signal a building product pipeline that supports future revenue growth. This data is published weekly on the respective regulatory websites.

Compare each company’s export revenue mix across geographies. Caplin’s 100% emerging market focus and Ajanta’s Africa dominance provide specific macroeconomic sensitivities that investors should map against their broader portfolio construction.

Verify all data on NSE (nseindia.com) or BSE (bseindia.com) before investing. Quarterly pharma earnings calls include product-level and geography-level revenue disclosures that provide much more useful analysis than the consolidated topline.

Conclusion: Top Pharma Stocks Under the Radar in India

India’s pharmaceutical export opportunity is not limited to Sun Pharma and Cipla. Caplin Point Laboratories, Neuland Laboratories, Marksans Pharma, Sudeep Pharma, and Ajanta Pharma each occupy differentiated positions in the global generics and API supply chain with strong regulatory standing and competitive financial profiles. These under the radar pharma stocks are shared for research and educational purposes only. Please consult a SEBI-registered advisor before investing.

The five pharma stocks discussed in this article are Caplin Point Laboratories, Neuland Laboratories, Marksans Pharma, Sudeep Pharma, Ajanta Pharma. Each of these pharma stocks carries unique risks and opportunities. Always verify current data on NSE (nseindia.com) or BSE (bseindia.com) before making any investment decision in these or any other pharma stocks.